Myosin light chain mutations in familial hypertrophic cardiomyopathy: phenotypic presentation and frequency in Danish and South African populations

Editor—Familial hypertrophic cardiomyopathy (FHC) is an autosomal dominant disease, which may afflict as many as 1 in 500 subjects.1 The disease is characterised by an unexplained local or general myocardial hypertrophy and by myocyte disarray.2 Molecular genetic studies have so far identified nine disease associated genes, all of which encode sarcomeric proteins. The two genes in which most mutations have been described are the β-myosin heavy chain ( MYH7 )3 and the myosin binding protein C ( MYBPC3 ) genes,4 each of which may account for up to 30% of all familial cases. Mutations in α-tropomyosin ( TPM1 ),5troponin T ( TNNT2 ),5 6troponin I ( TNNI3 ),6 cardiac α-actin ( ACTC ),7 titin ( TTN ),8 and the essential ( MYL3 ) and the regulatory ( MYL2 ) myosin light chain genes have also been associated with FHC.9 This pronounced genetic heterogeneity may be the principal cause of the phenotypic variability that is seen in FHC. Thus, mutations in TNNT2 seem to be associated with sudden death at a young age,10 11 whereas families with mutations in MYBPC3 are generally characterised by progressive hypertrophy and a late onset of clinical manifestation.12 13 Furthermore, it has been proposed that a certain rare form of hypertrophic cardiomyopathy (HCM), asymmetric septal hypertrophy predominantly confined to the midventricular region, known as the midventricular hypertrophy (MVH) phenotype, may be associated with mutations in the two myosin light chain genes.9 However, limited and contradictory clinical information is available on FHC caused by mutations in these genes.9 14 We have studied MYL2 and MYL3 in 68 consecutively collected FHC families from Denmark and in 130 probands from South Africa. We established the frequency of myosin light chain mutations and assessed whether mutations in these two genes do cause a distinct …

[1]  J. Roelandt,et al.  Prevalence of dignostic abnormalities in patients with genetically transmitted asymmetric septal hypertrophy. , 1979, The American journal of cardiology.

[2]  S. Solomon,et al.  Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. , 1989, The New England journal of medicine.

[3]  J. Seidman,et al.  A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation , 1990, Cell.

[4]  C. Sanders,et al.  Structural requirement of the regulatory light chain of smooth muscle myosin as a substrate for myosin light chain kinase. , 1994, The Journal of biological chemistry.

[5]  Christine E. Seidman,et al.  α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere , 1994, Cell.

[6]  K. Trybus,et al.  Coupling of ATPase activity and motility in smooth muscle myosin is mediated by the regulatory light chain , 1994, The Journal of cell biology.

[7]  J. Seidman,et al.  Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. , 1995, The New England journal of medicine.

[8]  J. Beckmann,et al.  Cardiac myosin binding protein–C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[9]  P. Brink,et al.  Clinical and prognostic evaluation of familial hypertrophic cardiomyopathy in two South African families with different cardiac beta myosin heavy chain gene mutations. , 1995, British heart journal.

[10]  W. Williams,et al.  Hypertrophic cardiomyopathy. Clinical spectrum and treatment. , 1995, Circulation.

[11]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[12]  W. McKenna,et al.  Hypertrophic cardiomyopathy — pathology and pathogenesis , 1995, Histopathology.

[13]  I. Rayment,et al.  Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle , 1996, Nature Genetics.

[14]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[15]  W. Mckenna,et al.  Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. , 1997, Heart.

[16]  M. Komajda,et al.  Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. , 1997, Circulation.

[17]  H. Watkins,et al.  Sudden death due to troponin T mutations. , 1997, Journal of the American College of Cardiology.

[18]  M. Matsuzaki,et al.  Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy , 1997, Nature Genetics.

[19]  Pascale Richard,et al.  Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy , 1998, Journal of Molecular Medicine.

[20]  M. Komajda,et al.  Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. , 1998, Circulation.

[21]  M Hiroe,et al.  Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. , 1999, Biochemical and biophysical research communications.

[22]  A. Børglum,et al.  α-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy , 1999 .

[23]  Familial hypertrophic cardiomyopathy associated with a novel missense mutation affecting the ATP-binding region of the cardiac beta-myosin heavy chain. , 1999, Journal of molecular and cellular cardiology.

[24]  M. Gautel,et al.  cAPK‐phosphorylation controls the interaction of the regulatory domain of cardiac myosin binding protein C with myosin‐S2 in an on‐off fashion , 1999, FEBS letters.

[25]  J. Vuust,et al.  High‐throughput single‐strand conformation polymorphism analysis by automated capillary electrophoresis: Robust multiplex analysis and pattern‐based identification of allelic variants , 1999, Human mutation.

[26]  J. Moolman-Smook,et al.  The origins of hypertrophic cardiomyopathy-causing mutations in two South African subpopulations: a unique profile of both independent and founder events. , 1999, American journal of human genetics.

[27]  A. Børglum,et al.  Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. , 1999, The Journal of clinical investigation.